Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 12, 2014, Pages 4438-4446

  Mercado, Moises ^a,b   Gonzalez, Baldomero ^a,b   Vargas, Guadalupe ^a   Ramirez, Claudia ^a,b   Espinosa De Los Monteros, Ana Laura ^a   Sosa, Ernesto ^a   Jervis, Paola ^a   Roldan, Paola ^a   Mendoza, Victoria ^a   López Félix, Blas ^a   Guinto, Gerardo ^a,b  

^a HOSPITAL DE ESPECIALIDADES   (Mexico)

^b AMERICAN BRITISH COWDRAY MEDICAL CENTER   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; GROWTH HORMONE; OCTREOTIDE; SOMATOMEDIN C; HUMAN GROWTH HORMONE;

ACROMEGALY; ADULT; ARTICLE; CAUSE OF DEATH; COMORBIDITY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG DOSE INCREASE; FEMALE; FOLLOW UP; GROWTH HORMONE BLOOD LEVEL; HEART DISEASE; HUMAN; HYPERTENSION; HYPOPHYSIS ADENOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MEXICO; MORTALITY; PREDICTION; PREVALENCE; RETROSPECTIVE STUDY; SURVIVAL RATE; TERTIARY HEALTH CARE; TRANSSPHENOIDAL HYPOPHYSECTOMY; ADOLESCENT; AGED; BLOOD; COHORT ANALYSIS; COMPLICATION; EPIDEMIOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; SURVIVAL; TREATMENT OUTCOME; YOUNG ADULT;

ACROMEGALY; ADOLESCENT; ADULT; AGED; COHORT STUDIES; COMBINED MODALITY THERAPY; COMORBIDITY; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MEXICO; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84916618519     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-2670     Document Type: Article

References (32)

1. Melmed S. Acromegaly pathogenesis and treatment. J Clin Invest. 2009;119:3189-3202.
2. Dekkers OM, Biermasz NR, Pereira AM, Romijn JA, Vandenbroucke JP. Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab. 2008;93:61-67.
3. Sherlock,M, Ayuk J, Tomlinson JW, et al. Mortality in patients with pituitary disease. Endocr Rev. 2010;31:301-342.
4. Espinosa E, Ramirez C, Mercado M. The multimodal treatment of acromegaly: current status and future perspectives [published online June 9, 2014]. Endocr Metab Immune Disord Drug Targets. doi: 10.2174/1871530314666140609110308.
5. Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab. 2004;89: 1613-1617.
6. Mestron A, Webb SM, Astorga R, et al. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Español de Acromegalia, REA). Eur J Endocrinol. 2004;151:439-446.
7. Kauppinen-Mäkelin R, Sane T, Reunanen A, Välimäki MJ, et al. A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab. 2005;90:4081-4086.
8. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf). 1994;41:95-102.
9. Swearingen B, Barker FG 2nd, Katznelson L, et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab. 1998;83:3419-3426.
10. Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab. 2004;89:667-674.
11. Alexander L, Appleton D, Hall R, Ross WM, Wilkinson R. Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol (Oxf). 1980;12:71-79.
12. Bates AS, Van't Hoff W, Jones JM, Clayton RN. An audit of outcome of treatment in acromegaly. Q J Med. 1993;86:293-299.
13. Arosio M, Reimondo G, Malchiodi E, et al. Predictors of morbidity and mortality in acromegaly: an Italian survey. Eur J Endocrinol. 2012;167:189-198.
14. Bogazzi F, Colao A, Rossi G, et al. Comparison of the effects of primary somatostatin analogue therapy and pituitary adenomectomy on survival in patients with acromegaly: a retrospective cohort study. Eur J Endocrinol. 2013;169:367-376.
15. Nabarro JD. Acromegaly. Clin Endocrinol (Oxf). 1987;26:481-512.
16. Holdaway IM, Rajasoorya C. Epidemiology of acromegaly. Pituitary. 1999;2:29-41.
17. Mercado M, Espinosa de los Monteros AL, Sosa E, et al. Clinical-biochemical correlations in acromegaly at diagnosis and the real prevalence of biochemically discordant disease. Horm Res. 2004; 62:293-299.
18. Espinosa-de-los-Monteros AL, González B, Vargas G, Sosa E, Mercado M. Clinical and biochemical characteristics of acromegalic patients with different abnormalities in glucose metabolism. Pituitary. 2011;14:231-235.
19. Sherlock M, Reulen RC, Alonso AA, et al. ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly. J Clin Endocrinol Metab. 2009;94:4216-4223.
20. González B, Vargas G, Espinosa-de-los-Monteros AL, Sosa E, Mercado M. Efficacy and safety of radiotherapy in acromegaly. Arch Med Res. 2011;42:48-52.
21. Biermasz NR, Dekker FW, Pereira AM, et al. Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements. J Clin Endocrinol Metab. 2004;89:2789-2796.
22. Wright AD, Hill DM, Lowy C, Fraser TR. Mortality in acromegaly. Q J Med. 1970;39:1-16.
23. Holdaway IM, Bolland MJ, Gamble GD. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol. 2008;159:89-95.
24. Pokrajac A, Wark G, Ellis AR, Wear J, Wieringa GE, Trainer PJ. Variation in GH and IGF-I assays limits the applicability of international consensus criteria to local practice. Clin Endocrinol (Oxf). 2007;67:65-70.
25. Orme SM, McNally RJ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab. 1998; 83:2730-2734.
26. Popovic V, Damjanovic S, Micic D, et al. Increased incidence of neoplasia in patients with pituitary adenomas. The Pituitary Study Group. Clin Endocrinol (Oxf). 1998;49:441-445.
27. Baris D, Gridley G, Ron E, et al. Acromegaly and cancer risk: a cohort study in Sweden and Denmark. Cancer Causes Control. 2002;13:395-400.
28. Gullu BE, Celik O, Gazioglu N, Kadioglu P. Thyroid cancer is the most common cancer associated with acromegaly. Pituitary. 2010; 13:242-248.
29. Bałdys-Waligórska A, Krzentowska A, Gołkowski F, Sokołowski G, Hubalewska-Dydejczyk A. The prevalence of benign and malignant neoplasms in acromegalic patients. Endokrynol Pol. 2010;61: 29-34.
30. Ron E, Gridley G, Hrubec Z, Page W, Arora S, Fraumeni JF Jr. Acromegaly and gastrointestinal cancer. Cancer. 1991;68:1673-1677.
31. Ruchala M, Szczepanek-Parulska E, Fularz M, Wolinski K. Risks of neoplasms in acromegaly. Contemp Oncol (Pozn). 2012;16:111-117.
32. dos Santos MC, Nascimento GC, Nascimento AG, et al. Thyroid cancer in patients with acromegaly: a case-control study. Pituitary. 2013;16:109-114.